Parkinson’s

Professor Stephen Wallace harvesting engineered bacteria for analysis.
#Bacteria #Neuroscience #Parkinson's #University of Edinburgh

Edinburgh team makes Parkinson’s drugs from plastic bottles

A drug to treat Parkinson’s disease can be made from waste plastic bottles using a pioneering method, a study shows.  The approach harnesses bacteria to transform post-consumer plastic into L-DOPA, a frontline medication for the neurological disorder.  It is the first time a natural, biological… Read More

#News #Trending News

#Alzheimer's #Brain #Breast cancer #Dementia #Genetics #Immunology #Institute of Cancer Research #King's College London #Neuroscience #Parkinson's #Respiratory syncytial virus #Women's health

This week in Drug Discovery (9 – 13 March) 

News round-up for 9 – 13 March February by Bruno Quinney, Content Team at DDW.  This week, research on the brain has proved a popular theme, unlocking insights into Alzheimer’s, dementia and cancer. Elsewhere, a genetic target could provide new routes to breast cancer treatment.  The top stories: … Read More

#News

#Biomarkers #Drug discovery #Parkinson's #Protein chemistry / Proteomics #Webinar

Webinar: Large-scale proteomics enables early detection and disease interception

What if you could see diseases like Parkinson’s coming years before symptoms appear? In this webinar, hosted by DDW and supported by Standard BioTools, Benoit Lehallier, PhD, Senior Director, Data Science at Alkahest will share how SomaScan Technology, alongside complementary proteomic platforms, uncovers signals that predict disease risk… Read More

Webinar date:
Supported by Standard BioTools
#News

Neuron
#Funding #Lario Therapeutics #Neuroscience #Parkinson's #The Michael J Fox Foundation for Parkinson’s Research (MJFF)

$2.4m funds neuronal calcium channel platform for Parkinson’s

Lario Therapeutics has received a total of $2.4 million in grant funding from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and Wellcome to support the continued expansion of its neuronal calcium channel drug discovery platform.  With the proceeds of these awards, Lario is expanding its work in Parkinson’s… Read More

#Business & Investment #News

#Biomarkers #Drug discovery #Parkinson's #Protein chemistry / Proteomics #Webinar

Webinar: Is trajectory-based profiling the next frontier in precision medicine?

What if you could see diseases like Parkinson’s coming years before symptoms appear? In this webinar, hosted by DDW and supported by Standard BioTools, Benoit Lehallier, PhD, Senior Director, Data Science at Alkahest will share how SomaScan Technology, alongside complementary proteomic platforms, uncovers signals that predict disease risk… Read More

Webinar date:
Supported by Standard BioTools
#News

#AC Immune #Alzheimer's #Immunotherapy #Parkinson's

Are active immunotherapies the key to Alzheimer’s disease?

Andrea Pfeifer, Co-Founder and CEO of AC Immune, examines how active immunotherapies could lead to a better treatment of Alzheimer’s disease.   Alzheimer’s disease is still, after so many decades, one of the greatest public health challenges. It affects millions of patients and their families, with an annual global cost that is… Read More

#Exclusive Content

Parkinson's disease
#Biomarkers #Drug discovery #Parkinson's #Protein chemistry / Proteomics #Webinar

Webinar: Parkinson’s biomarkers detected 12 years pre-symptomatically

What if you could see diseases like Parkinson’s coming years before symptoms appear? In this webinar, hosted by DDW and supported by Standard BioTools, Benoit Lehallier, PhD, Senior Director, Data Science at Alkahest will share how SomaScan Technology, alongside complementary proteomic platforms, uncovers signals that predict disease risk… Read More

Webinar date:
Supported by Standard BioTools
#News

Neurons in Parkinson's disease
#Nautilus Biotechnology #Neurodegenerative disorders #Parkinson's #The Michael J Fox Foundation

$1.6m collaboration to advance Parkinson’s proteomics research 

A $1.6 million research effort is set to advance single-molecule proteomics research in Parkinson’s disease (PD).  Life sciences company Nautilus Biotechnology has partnered with Weill Cornell Medicine-Qatar (WCM-Q) and The Michael J Fox Foundation (MJFF) to study the connection between the alpha-synuclein (aSyn) protein and PD.   The project will combine WCM-Q’s lab expertise in… Read More

#Business & Investment #News

Researcher in a medical lab
#Biomarkers #Drug discovery #Parkinson's #Protein chemistry / Proteomics #Webinar

Webinar: Predict disease risk long before diagnosis

What if you could see diseases like Parkinson’s coming years before symptoms appear? In this webinar, hosted by DDW and supported by Standard BioTools, Benoit Lehallier, PhD, Senior Director, Data Science at Alkahest will share how SomaScan Technology, alongside complementary proteomic platforms, uncovers signals that predict disease risk… Read More

Webinar date:
Supported by Standard BioTools
#News

#Allergy #Biomarkers #Biotech #Breast cancer #Europe #HER2 #Immune cells #Neurology #Oncology #Pancreatic cancer #Parkinson's #Therapeutic targets #Tokyo University of Science #Tumour microenvironment (TME) #UK government

DDW Highlights: 3 February 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week’s discoveries into Parkinson’s disease, allergies and common cancers could shape drug development. Elsewhere,… Read More

#Podcasts

#Allergy #Biomarkers #Biotech #Breast cancer #Europe #HER2 #Immune cells #Neurology #Oncology #Pancreatic cancer #Parkinson's #Therapeutic targets #Tokyo University of Science #Tumour microenvironment (TME) #UK #UK government

This week in Drug Discovery (26 – 30 January) 

News round-up for 26 – 30 January by Bruno Quinney, Content Team at DDW.  This week in DDW, discoveries into Parkinson’s disease, allergies and common cancers could shape drug development. Elsewhere, why is the UK leading Europe’s biotech market? The top stories:    Parkinson’s could be identified in… Read More

#News

Neuroscience Parkinson's disease
#Neurology #Norway #Parkinson's #Sweden

Parkinson’s could be identified in the blood, study shows 

Early signs of Parkinson’s disease can be identified in the blood, new research suggests.  In a new study published in npj Parkinson’s Disease, a research team from Chalmers University of Technology, Sweden and Oslo University Hospital, Norway identified biomarkers for Parkinson’s disease in its earliest stages, before extensive brain damage has occurred. Read More

#News

#Biomarkers #Drug discovery #Parkinson's #Protein chemistry / Proteomics #Webinar

Webinar: Mapping disease trajectories with proteomics

What if you could see diseases like Parkinson’s coming years before symptoms appear? In this webinar, hosted by DDW and supported by Standard BioTools, Benoit Lehallier, PhD, Senior Director, Data Science at Alkahest will share how SomaScan Technology, alongside complementary proteomic platforms, uncovers signals that predict disease risk… Read More

Webinar date:
Supported by Standard BioTools
#News

#Biomarkers #Drug discovery #Parkinson's #Protein chemistry / Proteomics #Webinar

From plasma to prediction: Mapping disease trajectories with proteomics at unprecedented scale

What if you could see disease coming years before symptoms appear? Chronos makes that vision a reality. Built on 100 million plasma samples from six million US donors, the platform combines real-world clinical data with high-resolution proteomics to chart molecular changes across time and populations. In this… Read More

Webinar date:
Supported by Standard BioTools
#Webinars

Node structures in the central nervous system
#Alzheimer's #Biotech #CNS #Insilico Medicine #Parkinson's

Insilico and Hygtia Therapeutics partner on CNS disease drug 

Biotechnology companies Insilico Medicine and Hygtia Therapeutics have announced a co-development collaboration agreement for Insilico’s ISM8969.  The partnership will look to accelerate the global advancement of ISM8969, an orally available, brain penetrant NLRP3 inhibitor for Central Nervous System (CNS) disorders.   The NLRP3 inflammasome is a critical component of the innate immune system but its aberrant activation is recognised… Read More

#Business & Investment #News

Parkinson's disease
#Japan #Neurodegenerative disorders #Parkinson's

Research reveals therapeutic target for Parkinson’s 

Researchers in Japan have revealed a potential new therapeutic target for Parkinson’s disease.  Scientists at Juntendo University found that liquid droplets of the protein ubiquilin-2 act as a catalyst for the aggregation of a-synuclein, a protein in the brain which is associated with neurodegenerative disorders. Ubiquilin-2 droplets… Read More

#News